LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
Index 603Cancer survivors, functional
limitation reported by, 575,
579
Cancer susceptibility syndromes,
screening for, 34, 45
Cancer therapeutic vaccines,
Simon’s Phase 2.5 design, 185,
192
CA-125, ovarian cancer and, 306,
311
Capecitabine, 161, 170, 234
Capillary leak syndrome, 128,
132–133
Carboplatin
in NSCLC treatment, 206, 211
in SCLC treatment, 209, 213
Carcinoembryonic antigen (CEA),
106, 110, 219
Carcinogenesis, 58, 64
Carcinogenic agents
oncogenes and, 58, 63
tumor suppressor gene and, 58,
63
Carcinoid syndrome, 211–212
Carcinoid tumors, 355, 362
Carcinoma, laparoscopic colectomy
for, 79, 82
Cardiac dysfunction, early
detection of, 554, 558–559
Cardiac irradiation, heart disease
and, 554, 558
Cardiac toxicity, acute, 526, 531
Cardiotoxicity, mechanism for, 124,
130
Carotene and Retinol Efficacy Trial
(CARET), 139
Case-control studies, 61, 66
bias in, 61, 66
Caspase cascade, 98, 102
Caspases, activation of, 96, 101
Caspofungin, in persistent
neutropenic fever, 540, 546
Castleman’s disease, causes of, 414,
429
Catenins, 31
Catheter
infection in, 162, 170
removal, indication for, 162, 170
CBC.SeeComplete blood count
(CBC)
CD117 (C-Kit) stain, 366, 371
CDH1.SeeE-cadherin gene
C. difficilecolitis, 542, 547
CDK.SeeCyclin-dependent kinases
(CDK)
CDX2 and colon cancer, 161, 170
CEA.SeeCarcinoembryonic
antigen (CEA)
CEBPA gene and AML, 443Cefepime, in neutropenic patients
with fever, 540, 546
Ceftazidime, in neutropenic
patients with fever, 540, 546
Ceftriaxone, for brain abscesses in
immunocompetent patients,
543, 548
Celecoxib, 139
Celiac ganglion block, 570
Celiac plexus block, and diarrhea,
553, 557
Cell-cycle exit, 18, 25
Cell lysis, 20, 28
Cell, mismatch repair machinery of,
4, 11
Cellular senescence, 47
Centers for Disease Control and
Prevention (CDC), 545
Central nervous system (CNS), 441,
447
neoplasms of, 383–392
prophylaxis, 441, 447
risk of, 416
Central venous catheters,
prophylactic anticoagulation
for, 552, 556
CER.SeeComparative effectiveness
research (CER)
Cerebrospinal fluid (CSF), 498
Cervical cancer
causes of, 315, 323
5FU with cisplatin, 317, 325
HIV and, 316
HPV and, 39, 51, 106, 111, 143,
315, 323, 324
HPV-16 and, 39, 51
lymph-vascular space invasion in,
316
microinvasive carcinoma and,
324
MRI in, 168, 181
myometrial invasion of, 168, 181
nodal involvement, 316, 324
pathogenesis of, 39, 51
PET scanning of, 317, 325
radiation therapy, 317, 325
smoking and, 39, 51
staging of, 317, 324–325
surgery in, 317, 325
tumor size, 316, 324
in United States, 315, 323
Cervical intraepithelial neoplasia
(CIN), 316
Cetuximab, 129, 199
colorectal cancer and, 98, 103,
272, 277
in colorectal cancer treatment, 97,
102
for SCCHN treatment, 197, 201Chaparral, and hepatotoxicity, 591,
595
CHART.SeeContinuous
hyperfractionated accelerated
radiation therapy (CHART)
Chemoradiation, for SCCHN, 197,
200–201
Chemotherapy, 368, 373
adjuvant, 368, 372, 373
for bladder cancer, 281, 290
for breast cancer, 337, 346
combination, 367, 372
for endometrial cancer, 321, 328,
329
for gastric cancer, 236, 242
goals of, 96, 100
for nasopharyngeal cancer, 201
for NSCLC, 208, 212
for ovarian cancer, 308, 309, 312,
314
for pancreatic cancer, 245, 250
preoperative, 368, 372
for prostate cancer, 286, 294
for SCLC, 207, 211
for small cell lung cancer, 503,
506
Chemotherapy-induced diarrhea,
agents for, 553, 557
Chemotherapy-induced nausea and
vomiting (CINV), 552, 556
acute, 556
anticipatory, 556
delayed, 553, 556, 557
patient-related factors for, 552,
556
treatment-related risk factors for,
556
Chemotherapy-induced pulmonary
toxicity, risk factors for, 554,
558
Chest lesion, sonography for,
165
Chest radiograph, 396, 406
Childhood cancers, 393–412
characteristics of, 393, 404
Childhood lymphomas
ataxia telangiectasia, 414
risk of, 414, 428
Wiskott-Aldrich, 414
X-linked lymphoproliferative
syndrome, 414
Child-Pugh A cirrhosis, 255
Child-Pugh C cirrhosis, 165, 175
Child-Pugh score, 253, 257
cHL.SeeClassic Hodgkin’s
lymphoma (cHL)
Cholangiocarcinoma, 254, 258
chronic portal bacteremia and
portal phlebitis, 253